Aryl Hydrocarbon Receptor Inhibition Restores Indoxyl Sulfate-Mediated Endothelial Dysfunction in Rat Aortic Rings

Chronic kidney disease is associated with elevated levels of uremic toxins, including indoxyl sulfate. These toxins contribute to cardiovascular disease through mechanisms that remain partially understood. Prior research has shown that indoxyl sulfate activates the aryl hydrocarbon receptor, a transcription factor linked to oxidative stress. However, the specific role of AhR in vascular endothelial dysfunction is unclear. This gap motivated an investigation into how AhR inhibition might counteract the effects of indoxyl sulfate. Existing studies have identified CYP1A1 as a downstream target of AhR activation. Yet, the extent to which AhR inhibition can restore endothelial function is not well established. No prior work had resolved whether AhR antagonists could reverse oxidative stress markers in vascular tissues. This uncertainty drove the need for an experimental approach using rat aortic rings. The study aimed to clarify whether AhR inhibition could mitigate the endothelial damage caused by indoxyl sulfate. Understanding these mechanisms could help identify new therapeutic strategies for cardiovascular disease in CKD patients.

The study aimed to evaluate the effects of AhR inhibition on IS-induced endothelial dysfunction in rat aortic rings. Researchers focused on whether blocking AhR could restore endothelium-dependent relaxation and redox balance. The specific problem addressed was the role of AhR in IS-mediated vascular damage. Motivation came from the need to explore novel therapies for CVD in CKD patients. The experiment tested the hypothesis that AhR antagonists could counteract oxidative stress and endothelial dysfunction. The study design included aortic rings exposed to IS with and without CH223191. The goal was to determine if AhR inhibition could restore vascular function. The findings could provide insights into potential treatments for CKD-related cardiovascular complications.

The study used aortic rings from Sprague Dawley rats to assess vascular function. Tissues were exposed to four conditions: control, IS alone, IS with low-dose CH223191, and IS with high-dose CH223191. Endothelium-dependent relaxation was measured using a myograph system. Redox markers were analyzed after exposure to determine oxidative stress levels. The concentration of IS was set at 300 μM to mimic uremic conditions. CH223191 was used at 1 μM and 10 μM to test dose-dependent effects. Tissue samples were collected for protein expression analysis. The study focused on CYP1A1, nitro-tyrosine, NOX4, superoxide, and eNOS as key markers.

IS exposure reduced endothelium-dependent relaxation by 42% compared to controls. This effect was reversed with increasing concentrations of CH223191. IS increased CYP1A1 expression, a marker of AhR activation. Nitro-tyrosine levels also rose, indicating oxidative stress. NOX4 and superoxide levels increased, while eNOS decreased. CH223191 at 10 μM restored all markers to control levels. The highest dose of CH223191 showed the most significant recovery. These findings suggest that AhR inhibition can counteract IS-induced endothelial dysfunction.

The study demonstrates that IS-induced AhR activation leads to endothelial dysfunction and oxidative stress. AhR inhibition with CH223191 restored vascular relaxation and redox balance. The findings suggest that AhR antagonists may provide a novel therapy for CVD in CKD patients. The results confirm a role for AhR in IS-mediated vascular damage. The study supports further investigation into AhR inhibition as a treatment strategy. No prior work had shown such a direct link between AhR and endothelial dysfunction. The authors propose that targeting AhR could be a promising approach. The findings do not suggest AhR inhibition is essential but highlight its potential therapeutic value.